- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Robert Gabbay Discusses How Kerendia's Recommended Drug Status Could Impact Patients With CKD, Diabetes
Robert Gabbay, MD, PhD, of the American Diabetes Association (ADA), talks about the impact that finerenone could have on patients with kidney disease and diabetes.
Robert Gabbay, MD, PhD, of the American Diabetes Association (ADA), talks about the impact that finerenone, a drug that was added to the ADA's list of recommended drugs for chronic kidney disease (CKD) management, could have on patients with CKD and diabetes.
Transcript
What impact do you think adding Kerendia (finerenone) as a recommended medication for the CKD and diabetes populations will have on patient experience?
We're driven by improving the lives of people affected by diabetes. And so, the underlying reason for doing this standards of care is really to help guide clinicians in the best care of their patients. And finerenone is a new treatment that can significantly improve outcomes for people with diabetes. Our hope is that these standards helped to bring the attention to clinicians about this new treatment option.
Long-Term Benefits Show the Value of Upfront Investments in Value-Based Care
October 17th 2024Miriam Godwin, CMMI, National Kidney Foundation, touches on the gaps in kidney care that public policy can address, as well as the importance of thinking about the long-term benefits of value-based care.
Read More
More Needs to Be Done to Reduce Racial Disparities in Home Dialysis
March 24th 2023On this episode of Managed Care Cast, we speak with Virginia Wang, PhD, and Matthew L. Maciejewski, PhD, who talk about their recent study on racial disparities in home dialysis, and what more needs to be done to increase uptake and reduce disparities in home dialysis for non-White patients.
Listen
FDA Approves Vadadustat for Anemia in Patients With CKD Undergoing Dialysis
March 28th 2024The FDA approved vadadustat (Vafseo), an oral medication, to treat anemia in adult patients with chronic kidney disease (CKD) on dialysis for at least 3 months. This fills a need for a new treatment option as anemia is common in these patients and can significantly impact their quality of life.
Read More
